Introducing the Viennalab PGX-5FU DPYD XL StripAssay® – the comprehensive solution for accurate identification of the four most clinically relevant variants in the dihydropyrimidine dehydrogenase (DPYD) gene, with therapeutic relevance for fluoropyrimidine treatment. Our kit is designed to increase patient safety and reduce the risk of treatment-related toxicity in cancer therapy.

Fluoropyrimidines, including 5-Fluorouracil, Capecitabine, and Tegafur, are widely used in cancer therapy, but some patients may develop severe treatment-related toxicity. The Viennalab PGX-5FU XL StripAssay® covers the four most clinically relevant variants in the DPYD gene that can impair the activity of dihydropyrimidine dehydrogenase (DPD), a key metabolic enzyme for fluoropyrimidine treatment.

The European Medicines Agency recommends DPYD genotype-guided fluoropyrimidine dosing to increase patient safety, and the Viennalab PGX-5FU XL StripAssay® is designed to support these guidelines. By accurately identifying the patient’s DPYD genotype, clinicians can personalize the fluoropyrimidine dosage to individual patient needs, reducing the risk of treatment-related toxicity and improving patient outcomes.

Trust in Viennalab’s expertise and experience in molecular diagnostics to provide you with reliable and easy-to-use results for your laboratory workflow. Take the first step towards achieving personalized fluoropyrimidine-based therapy and improving patient outcomes – add the Viennalab PGX-5FU XL StripAssay® to your laboratory today.